



High-Impact Publications in Cancer Research, January 2022–July 2023

ZE5 Cell Analyzer Publications

Aikins ME et al. (2022).

Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma.
J Control Release 351, 872–882.

Apavaloaei A et al. (2022).

Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers.
Cell Rep 40, 111241.

Bhatia S et al. (2022).

EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment.
Nat Commun 13, 3535.

Blokon-Kogan D et al. (2022).

Membrane anchored IL-18 linked to constitutively active TLR4 and CD40 improves human T cell antitumor capacities for adoptive cell therapy.
J Immunother Cancer 10, e001544.

Cordo' V et al. (2022).

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Nat Commun 13, 1048.

Crees ZD et al. (2023).

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: A randomized phase 3 trial.
Nat Med 29, 869–879.

Du W et al. (2023).

WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer.
J Exp Med 220, e20220503.

Evgin L et al. (2022).

Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. *Sci Transl Med* 14, eabn2231.

Hattori T et al. (2023).

Creating MHC-restricted neoantigens with covalent inhibitors that can be targeted by immune therapy. *Cancer Discov* 13, 132–145.

Jang HJ et al. (2023).

Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens. *J Immunother Cancer* 11, e006472.

Kim MY et al. (2022).

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. *Nat Commun* 13, 3296.

Lidström T et al. (2023).

Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer. *Cancer Immunol Res* 11, 72–92.

Maniar R et al. (2023).

Self-renewing CD8+ T-cell abundance in blood associates with response to immunotherapy. *Cancer Immunol Res* 11, 164–170.

Mao C et al. (2022).

In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade. *J Immunother Cancer* 10, e005834.

Merlotti A et al. (2023).

Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. *Sci Immunol* 8, eabm6359.

Ng KW et al. (2023).

Antibodies against endogenous retroviruses promote lung cancer immunotherapy. *Nature* 616, 563–573.

O'Neal J et al. (2022).

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. *Leukemia* 36, 1,625–1,634.

Song Y et al. (2022).

Albumin nanoparticle containing a PI3K γ inhibitor and paclitaxel in combination with α -PD1 induces tumor remission of breast cancer in mice. *Sci Transl Med* 14, eabl3649.

Velez-Delgado A et al. (2022).

Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming.
Cell Mol Gastroenterol Hepatol 13, 1,673–1,699.

Yao L et al. (2023).

Single-cell discovery and multiomic characterization of therapeutic targets in multiple myeloma.
Cancer Res 83, 1,214–1,233.

Visit [bio-rad.com/ZE5Cancer](https://www.bio-rad.com/ZE5Cancer) for more information.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. All trademarks used herein are the property of their respective owner.
© 2023 Bio-Rad Laboratories, Inc.



**Bio-Rad
Laboratories, Inc.**

Life Science
Group

Website [bio-rad.com](https://www.bio-rad.com) **USA** 1 800 424 6723 **Australia** 61 2 9914 2800 **Austria** 00 800 00 24 67 23 **Belgium** 00 800 00 24 67 23 **Brazil** 4003 0399
Canada 1 905 364 3435 **China** 86 21 6169 8500 **Czech Republic** 00 800 00 24 67 23 **Denmark** 00 800 00 24 67 23 **Finland** 00 800 00 24 67 23
France 00 800 00 24 67 23 **Germany** 00 800 00 24 67 23 **Hong Kong** 852 2789 3300 **Hungary** 00 800 00 24 67 23 **India** 91 124 4029300 **Israel** 0 3 9636050
Italy 00 800 00 24 67 23 **Japan** 81 3 6361 7000 **Korea** 82 080 007 7373 **Luxembourg** 00 800 00 24 67 23 **Mexico** 52 555 488 7670
The Netherlands 00 800 00 24 67 23 **New Zealand** 64 9 415 2280 **Norway** 00 800 00 24 67 23 **Poland** 00 800 00 24 67 23 **Portugal** 00 800 00 24 67 23
Russian Federation 00 800 00 24 67 23 **Singapore** 65 6415 3188 **South Africa** 00 800 00 24 67 23 **Spain** 00 800 00 24 67 23 **Sweden** 00 800 00 24 67 23
Switzerland 00 800 00 24 67 23 **Taiwan** 886 2 2578 7189 **Thailand** 66 2 651 8311 **United Arab Emirates** 36 1 459 6150 **United Kingdom** 00 800 00 24 67 23

